Journal: Cell Research

Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma

doi: 10.1038/s41422-025-01200-w

Figure Lengend Snippet: a Mutation landscape of pre-invasive (AAH/AIS/MIA, left) and invasive adenocarcinoma (right) samples. b MAP2K1 mutations identified in the study cohort. c MAP2K1 mutations identified in our previous study of 98 pre-invasive and 99 invasive adenocarcinoma samples. d Comparison of tumor mutation burden between samples in this cohort and TCGA cohorts. e Landscape of somatic copy number alterations (SCNAs) in this study cohort, with pre-invasive samples at the top and invasive samples at the bottom. f Co-mutational status, showing the mutual exclusivity and co-occurrence of major oncogenes and tumor suppressor genes. Statistical significance was assessed using Fisher’s exact test.

Article Snippet: SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

Techniques: Mutagenesis, Comparison

Journal: Cell Research

Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma

doi: 10.1038/s41422-025-01200-w

Figure Lengend Snippet: a Study design of in vitro and in vivo experiments. b Western blot analysis of phosphorylated and total Mek1 and Erk in Trp53 −/− –ATII organoids. NC negative control group, WT group overexpressing WT MAP2K1 , MT group overexpressing MAP2K1 ΔE102−I103 . c Morphological changes (top), H&E staining (second row), and IHC of EpCAM (third row) and TTF-1 (bottom) in Trp53 −/− –ATII organoids after 5 days of culture. Scale bar, 50 µm. d Relative viability of organoids on days 1, 3, and 5. n = 3 biological replicates. e Relative organoid area of organoids on day 5. f – h Growth curve ( f ), end point illustration ( g , scale bar, 1 cm), and tumor weight ( h ) of Trp53 −/− ( n = 4), Trp53 −/− ; MAP2K1 WT ( n = 4), and Trp53 −/− ; MAP2K1 MT ( n = 4) allografts. i H&E staining and IHC of TTF-1, KRT7, and EpCAM of the Trp53 −/− ; MAP2K1 MT organoid allograft at the experiment endpoint (day 48). Scale bar, 50 µm. j Efficacy of SM1-71, an inhibitor of MAP2K1, in treating MAP2K1 MT , MAP2K1 WT , and negative-control Ba/F3 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

Techniques: In Vitro, In Vivo, Western Blot, Negative Control, Staining

Journal: Cell Research

Article Title: Genomic and transcriptomic dynamics in the stepwise progression of lung adenocarcinoma

doi: 10.1038/s41422-025-01200-w

Figure Lengend Snippet: Analysis of 1008 LUAD samples identified the MAP2K1 E102–I103 deletion as a potential driver of LUAD initiation. LUAD progression was associated with increased genomic instability, including a higher tumor mutational burden, increased SCNA burden, and increased structural variations. Furthermore, patients with site-specific recurrences exhibited distinct genomic and transcriptomic profiles.

Article Snippet: SM1-71 (MCE, Cat# HY-136848) was used as a MAP2K1 inhibitor.

Techniques:

Journal: BMC Cancer

Article Title: MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3

doi: 10.1186/1471-2407-13-469

Figure Lengend Snippet: The expression of MAP2K3 in human HCC tissues determined by IHC

Article Snippet: The membranes were probed with rabbit anti-MAP2K3 antibody and anti-GAPDH antibody (Boster, Wuhan, China) or (1:200, Boster, Wuhan, China) were for the interested protein MAP2K3 and endogenous GAPDH for loading control, respectively.

Techniques: Expressing, Immunohistochemistry

Journal: BMC Cancer

Article Title: MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3

doi: 10.1186/1471-2407-13-469

Figure Lengend Snippet: Validation of MAP2K3 mRNA as a target of miR-21. (A) : Sequence of potential binding site of miR-21 in the 3’UTR of MAP2K3 mRNA (top panel), mutations were introduced into the binding site for generation of mutated MAP2K3 3’TUR (bottom panel). ( B and C ): Validation of miR-21 target using MAP2K3 3’UTR luciferase reporter. Cells co-transfected with pMIR-Report/MAP2K3 3’UTR (WT) or pMIR-Report/Mut-MAP2K3 3’UTR (Mut) and pAd/pri-miR-21 (B) , pAd/miR-21/inhibitor (C) , and pAd/con plasmids showed a decreased luciferase activity in pAd/pri-miR-21 cells (B) . Luciferase activity after site directed mutagenesis of the 3’UTR of MAP2K3 mRNA in the miR-21 seed sequence (pMIR-Report/Mut-MAP2K3) was significantly higher with respect to the pMIR-Report/MAP2K3 vector transfected cells ( B and C ). Results represented the mean ± SD from three independent triplicated experiments (N=9).

Article Snippet: The membranes were probed with rabbit anti-MAP2K3 antibody and anti-GAPDH antibody (Boster, Wuhan, China) or (1:200, Boster, Wuhan, China) were for the interested protein MAP2K3 and endogenous GAPDH for loading control, respectively.

Techniques: Biomarker Discovery, Sequencing, Binding Assay, Luciferase, Transfection, Activity Assay, Mutagenesis, Plasmid Preparation

Journal: BMC Cancer

Article Title: MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3

doi: 10.1186/1471-2407-13-469

Figure Lengend Snippet: miR-21 targets MAP2K3 mRNA. The HepG2 cells were infected with Ad/pri-miR-21, Ad/miR-21/inhibitor or Ad/con adenoviral vector. The expression of MAP2K3 was detected by immunoblotting analysis against anti-MAP2K3 antibody. Compared with Ad/con group, *: p <0.05. Data in A represented the mean ± SD from three independent triplicated experiments (N=9).

Article Snippet: The membranes were probed with rabbit anti-MAP2K3 antibody and anti-GAPDH antibody (Boster, Wuhan, China) or (1:200, Boster, Wuhan, China) were for the interested protein MAP2K3 and endogenous GAPDH for loading control, respectively.

Techniques: Infection, Plasmid Preparation, Expressing, Western Blot

Journal: PLoS ONE

Article Title: IGF-1 Induces GHRH Neuronal Axon Elongation during Early Postnatal Life in Mice

doi: 10.1371/journal.pone.0170083

Figure Lengend Snippet: Primary and secondary antibodies.

Article Snippet: Mek1 , Polyclonal Anti- Dual specificity mitogen-activated protein kinase kinase 1, MAP2K1 , Boster Biological Technology, PA1376 , Rabbit, polyclonal , 1/ 3000.

Techniques: Immunocytochemistry, Purification, Plasmid Preparation